MUC1 and MUC4: Switching the emphasis from large to small

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 261-271

  Albrecht, Huguette ^a   Carraway, Kermit L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

subunit; biomarker; breast cancer; MUC1; MUC4; oncogene

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; CA 15-3 ANTIGEN; CANCER VACCINE; GO 201; GO 202; MICRORNA; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 4; PEPTIDE DERIVATIVE; STIMUVAX; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ALPHA CHAIN; ARTICLE; BETA CHAIN; BREAST CANCER; CANCER IMMUNOTHERAPY; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ALLELES; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; MUCIN-1; MUCIN-4; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79960049174     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1017     Document Type: Article

References (49)

1. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286.
2. Kufe DW. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer;9:874.
3. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339.
4. Moniaux N, Escande F, Batra SK, Porchet N, Laine A, Aubert JP. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 2000;267:4536.
5. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: Changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001; 6:355.
6. Carraway KL, 3rd, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007;78:1.
7. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol 1998;19(suppl1):1.
8. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993;53:5386.
9. Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2010;2:305.
10. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301.
11. Zhao Q, Barclay M, Hilkens J, et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer 2010;9:154.
12. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal- Eiras A. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 2001;69:1.
13. Komatsu M, Carraway CA, Fregien NL, Carraway KL. Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. J Biol Chem 1997;272: 33245.
14. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 2004;4:45.
15. Carson DD. The cytoplasmic tail of MUC1: a very busy place. Sci Signal 2008;1:pe35.
16. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26:1693.
17. Merlin J, Stechly L, de Beauce S, et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011;30:2514.
18. Behrens ME, Grandgenett PM, Bailey JM, et al. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene 2010;29:5667.
19. Kufe D. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010;29:5663.
20. Ahmad R, Rajabi H, Kosugi M, et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 2011;4:ra9.
21. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010;123(pt10):1716.
22. Huang L, Liao X, Beckett M, et al. MUC1-C Oncoprotein interacts directly with ATM and promotes the DNA damage response to ionizing radiation. Genes Cancer 2010;1:239.
23. Carraway KL, 3rd, Rossi EA, Komatsu M, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 1999;274:5263.
24. Funes M, Miller JK, Lai C, Carraway KL, 3rd, Sweeney C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 2006;281:19310.
25. Workman HC, Sweeney C, Carraway KL, 3rd. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 2009;69:2845.
26. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869.
27. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966.
28. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973.
29. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18:1295.
30. van der Vegt B, de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007;51:322.
31. Croce MV, Isla-Larrain MT, Rua CE, Rabassa ME, Gendler SJ, Segal-Eiras A. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem 2003;51:781.
32. Workman HC, Miller JK, Ingalla EQ, et al. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res 2009;11:R70.
33. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem 1999;45:630.
34. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287.
35. Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J Nucl Med 1993;34:1067.
36. Rubinstein DB, Karmely M, Ziv R, et al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 2006;66:11247.
37. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptinresistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473.
38. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1*is a determinant of trastuzumab (herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 2009; 118:113.
39. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002;99:783.
40. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: Preclinical studies. Expert Rev Vaccines 2008;7:951.
41. Finn OO, Banchereau J. Cancer vaccines: The state of the art. Semin Immunol 2010;22:103.
42. Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010;1798:2190.
43. Bitler BG, Menzl I, Huerta CL, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009;15:100.
44. Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009;69:5133.
45. Zhou J, Rajabi H, Kufe DW. Muc1-C oncoprotein is a target for small molecule inhibitors. Mol Pharmacol 2011;79:886.
46. Mahanta S, Fessler SP, Park J, Bamdad C. A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One 2008;3:e2054.
47. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010;70:378.
48. Jin C, Rajabi H, Kufe D. miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol 2010;37:61.
49. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. Mucin 1 oncoprotein expression is suppressed by the miR- 125b oncomir. Genes Cancer 2010;1:62.